<DOC>
	<DOC>NCT00158041</DOC>
	<brief_summary>Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously. The four targeted toxicities were nausea/vomiting, hypotension, generalized skin rash, and injection-site skin reactions.</brief_summary>
	<brief_title>Subcutaneous Amifostine Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>Institutional criteria for administration of amifostine Radiation therapy ECOG PS of at least 2 No distant mets Granulocyte count greater than 2000 Platelet count greater than 100,000 Creatinine less than 2.0 Allergy to amifostine Life expectancy less than 6 mos Investigational drug within last 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Amifostine</keyword>
	<keyword>Mucositis</keyword>
	<keyword>Nausea</keyword>
	<keyword>Hypotension</keyword>
	<keyword>Rash</keyword>
</DOC>